LON:VAL ValiRx (VAL) Share Price, News & Analysis GBX 0.72 +0.03 (+3.57%) As of 11:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ValiRx Stock (LON:VAL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ValiRx alerts:Sign Up Key Stats Today's Range 0.67▼ 0.7550-Day Range 0.52▼ 0.7752-Week Range 0.38▼ 2.37Volume5.61 million shsAverage Volume5.40 million shsMarket Capitalization£2.71 millionP/E RatioN/ADividend Yield0.63%Price TargetN/AConsensus RatingN/A Company Overview ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development. Read More Receive VAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VAL Stock News HeadlinesValiRx’s Cytolytix Advances Cancer Therapeutics with Key Patent and Platform DevelopmentsSeptember 1, 2025 | tipranks.comValiRx (LON:VAL) Stock Price Up 17.9% - Time to Buy?August 31, 2025 | americanbankingnews.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.September 5 at 2:00 AM | Investors Alley (Ad)ValiRx establishes new subsidiary for prostate cancer assetsAugust 26, 2025 | lse.co.ukValiRx Expands Prostate Cancer Portfolio with New SubsidiaryAugust 26, 2025 | tipranks.comValiRx Updates Evaluation Agreement with Stingray Bio for Cancer TherapeuticsAugust 5, 2025 | tipranks.comValiRx subsidiary Inaphaea agrees exclusive PredictRx licensing dealAugust 4, 2025 | lse.co.ukValiRx Partners with VoxCell for Advanced Cancer Model DevelopmentJuly 29, 2025 | tipranks.comSee More Headlines VAL Stock Analysis - Frequently Asked Questions How have VAL shares performed this year? ValiRx's stock was trading at GBX 0.65 at the beginning of the year. Since then, VAL shares have increased by 11.5% and is now trading at GBX 0.73. How were ValiRx's earnings last quarter? ValiRx plc (LON:VAL) announced its earnings results on Friday, June, 6th. The company reported ($1.45) earnings per share for the quarter. ValiRx had a negative net margin of 20,554.01% and a negative trailing twelve-month return on equity of 55.84%. How do I buy shares of ValiRx? Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Lloyds Banking Group (LLOY), IQE (IQE) and Scirocco Energy Plc (SOLO.L) (SOLO). Company Calendar Last Earnings6/06/2025Today9/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPetroleum And Natural Gas Current SymbolLON:VAL CIKN/A Webwww.valirx.com Phone+44-20-30084416FaxN/AEmployees5,450Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.71 million Net Margins-20,554.01% Pretax MarginN/A Return on Equity-55.84% Return on Assets-35.98% Debt Debt-to-Equity Ratio0.44 Current Ratio6.65 Quick Ratio1.27 Sales & Book Value Annual Sales£49.78 thousand Price / Sales54.90 Cash FlowGBX 0.01 per share Price / Cash Flow62.50 Book ValueGBX 2.67 per share Price / Book0.27Miscellaneous Outstanding Shares374,349,000Free FloatN/AMarket Cap£2.73 million OptionableNot Optionable Beta0.59 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:VAL) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ValiRx plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ValiRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.